These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 20384957)

  • 41. Voriconazole in newborns.
    Kohli V; Taneja V; Sachdev P; Joshi R
    Indian Pediatr; 2008 Mar; 45(3):236-8. PubMed ID: 18367773
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Severe phototoxicity associated with long-term voriconazole treatment.
    Vöhringer S; Schrum J; Ott H; Höger PH
    J Dtsch Dermatol Ges; 2011 Apr; 9(4):274-6. PubMed ID: 21050383
    [TBL] [Abstract][Full Text] [Related]  

  • 43. VFEND® (voriconazole)-associated hypoglycaemia without identified drug interaction.
    Lyoen M; Rostain F; Grimault A; Minello A; Sgro C
    Fundam Clin Pharmacol; 2013 Oct; 27(5):570-1. PubMed ID: 22834415
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Painful peripheral neuropathy associated with voriconazole use.
    Tsiodras S; Zafiropoulou R; Kanta E; Demponeras C; Karandreas N; Manesis EK
    Arch Neurol; 2005 Jan; 62(1):144-6. PubMed ID: 15642862
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and pharmacokinetics of coadministered voriconazole and anidulafungin.
    Dowell JA; Schranz J; Baruch A; Foster G
    J Clin Pharmacol; 2005 Dec; 45(12):1373-82. PubMed ID: 16291712
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Complex visual hallucinations induced by voriconazole].
    Fernández-Ruiz M; López-Medrano F; Gutiérrez E; Aguado JM
    Med Clin (Barc); 2009 Jun; 133(4):156-7. PubMed ID: 19540418
    [No Abstract]   [Full Text] [Related]  

  • 47. Voriconazole inhibition of vitamin A metabolism: are adverse events increased in cystic fibrosis patients?
    Cheng MP; Paquette K; Lands LC; Ovetchkine P; Théoret Y; Quach C
    Pediatr Pulmonol; 2010 Jul; 45(7):661-6. PubMed ID: 20575095
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Exacerbation of myasthenia gravis with voriconazole.
    Azzam R; Shaikh AG; Serra A; Katirji B
    Muscle Nerve; 2013 Jun; 47(6):928-30. PubMed ID: 23666793
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term visual safety of voriconazole in adult patients with paracoccidioidomycosis.
    Laties AM; Fraunfelder FT; Tomaszewski K; Goodrich J; Moreira AT; Sato MT; de Queiroz-Telles F
    Clin Ther; 2010 Dec; 32(13):2207-17. PubMed ID: 21316537
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics of voriconazole after oral administration of single and multiple doses in Hispaniolan Amazon parrots (Amazona ventralis).
    Sanchez-Migallon Guzman D; Flammer K; Papich MG; Grooters AM; Shaw S; Applegate J; Tully TN
    Am J Vet Res; 2010 Apr; 71(4):460-7. PubMed ID: 20367055
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adverse effects of voriconazole.
    Lohr L
    Orthopedics; 2004 May; 27(5):472-3. PubMed ID: 15181941
    [No Abstract]   [Full Text] [Related]  

  • 52. Voriconazole: a new triazole antifungal agent.
    Johnson LB; Kauffman CA
    Clin Infect Dis; 2003 Mar; 36(5):630-7. PubMed ID: 12594645
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation.
    Marty FM; Lowry CM; Cutler CS; Campbell BJ; Fiumara K; Baden LR; Antin JH
    Biol Blood Marrow Transplant; 2006 May; 12(5):552-9. PubMed ID: 16635790
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Voriconazole treatment for less-common, emerging, or refractory fungal infections.
    Perfect JR; Marr KA; Walsh TJ; Greenberg RN; DuPont B; de la Torre-Cisneros J; Just-Nübling G; Schlamm HT; Lutsar I; Espinel-Ingroff A; Johnson E
    Clin Infect Dis; 2003 May; 36(9):1122-31. PubMed ID: 12715306
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study.
    Lazarus HM; Blumer JL; Yanovich S; Schlamm H; Romero A
    J Clin Pharmacol; 2002 Apr; 42(4):395-402. PubMed ID: 11936564
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Voriconazole: serious adverse effects and interactions.
    Prescrire Int; 2007 Feb; 16(87):18. PubMed ID: 17326278
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Voriconazole: a broad spectrum triazole for the treatment of serious and invasive fungal infections.
    Maschmeyer G; Haas A
    Future Microbiol; 2006 Dec; 1(4):365-85. PubMed ID: 17661629
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fatal dysrhythmia following initiation of lansoprazole during a long-term course of voriconazole.
    Tsubokura M; Miura Y; Itokawa T; Murata K; Takei N; Higaki T; Murashige N; Kami M; Komatsu T
    J Clin Pharmacol; 2011 Oct; 51(10):1488-90. PubMed ID: 21098688
    [No Abstract]   [Full Text] [Related]  

  • 59. Treatment strategies for invasive aspergillosis in neutropenic patients: voriconazole or liposomal amphotericin-B?
    Pagano L; Valentini CG; Fianchi L; Caira M
    J Chemother; 2011 Feb; 23(1):5-8. PubMed ID: 21482486
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization.
    Chishimba L; Niven RM; Cooley J; Denning DW
    J Asthma; 2012 May; 49(4):423-33. PubMed ID: 22380765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.